IL17A and Sepsis: While sepsis induced a 100-fold increase in IL-17 (from 0.9 ± 0.4 to 100.2 ± 46.3 pg/mL, P < 0.001, n = 6 mice/group), neutralization of truncated procalcitonin (to 2.7 ± 1.0 pg/mL, P < 0.001), application of olcegepant, a procalcitonin receptor agonist during sepsis (to 3.4 ± 2.4 pg/mL, P < 0.001) as well as application of an inhibitor of dipeptidyl-peptidase 4 (DPP4) that inhibits the conversion of full-length to truncated procalcitonin (to 0.7 ± 6.3 pg/mL, P < 0.001) all nearly completely abolished the presence of IL-17 in septic mice plasma (Fig. 3f).